

## Disclosures

### Personal Commercial (18)

| Company Name                    | Relationship Category   | Compensation Level       | Topic Area(s)   |
|---------------------------------|---|--------------------------|---|
| <i>Self</i>                     |   |                          |   |
| Abbott Laboratories             | Stock   | Significant (>= \$5,000) | Prevention General Cardiology Invasive CV Angio and Interventions Vascular Medicine |
| AbbVie, Inc.                    | Stock   | Significant (>= \$5,000) | General Cardiology  |
| Amgen                           | Stock   | Significant (>= \$5,000) | Prevention General Cardiology   |
| Bristol-Myers Squibb            | Stock   | Significant (>= \$5,000) | General Cardiology Prevention   |
| Cardinal Health                 | Stock   | Significant (>= \$5,000) | Noninvasive Imaging   |
| Eli Lilly and Company           | Stock   | Significant (>= \$5,000) | General Cardiology  |
| General Electric                | Stock   | Modest (< \$5,000)       | Noninvasive Imaging   |
| INVIA Medical Imaging Solutions | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Noninvasive Imaging   |
| INVIA Medical Imaging Solutions | Research/Research Grants  | Significant (>= \$5,000) | Noninvasive Imaging   |
| Ionelix                         | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Noninvasive Imaging   |
| Medtronic                       | Stock   | Significant (>= \$5,000) | Invasive CV Angio and Interventions   |
| Merck                           | Stock   | Significant (>= \$5,000) | Prevention General Cardiology   |
| Mylan Laboratories              | Stock   | Modest (< \$5,000)       | General Cardiology Prevention   |
| Pfizer                          | Stock   | Significant (>= \$5,000) | General Cardiology  |
| Siemens                         | Research/Research Grants<br>‡ Investigator initiated research grant | Significant (>= \$5,000) | Noninvasive Imaging   |
| Singulex                        | Stock   | Significant (>= \$5,000) | Noninvasive Imaging   |
| Teva Pharmaceuticals            | Stock   | Modest (< \$5,000)       | Prevention General Cardiology   |
| Viartis                         | Stock   | Modest (< \$5,000)       | Other   |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (1)

| Year        | Case Title          | Represented                       | Description                                     | Compensation             |
|-------------|---------------------|-----------------------------------|---|--------------------------|
| <i>Self</i> |                     |                                   |   |                          |
| 2019        | Patent infringement | Defendant<br>‡ Jubilant DRAXimage | Infringement of design of Rb-82 infusion system | Significant (>= \$5,000) |

## Agreement

---

### **Certified Education Attestation** | Signed on 10/6/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### **Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/6/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### **Embargo** | Signed on 10/6/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### **On-Going Obligation Agreement** | Signed on 10/6/2025

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.